SCIENTIFIC REPORTS

OPEN

The role of P2X7 receptors in a rodent PCP-induced schizophrenia model

Bence Koványi^{1,2,†}, Cecilia Csölle^{1,†}, Stefano Calovi¹, Adrienn Hanuska³, Erzsébet Kató³, László Köles³, Anindya Bhattacharya⁴, József Haller⁵ & Beáta Sperlág¹

Received: 22 July 2016

Accepted: 18 October 2016

Published: 08 November 2016

P2X7 receptors (P2X7Rs) are ligand-gated ion channels sensitive to extracellular ATP. Here we examined for the first time the role of P2X7R in an animal model of schizophrenia. Using the PCP induced schizophrenia model we show that both genetic deletion and pharmacological inhibition of P2X7Rs alleviate schizophrenia-like behavioral alterations. In *P2rx7*^{+/+} mice, PCP induced hyperlocomotion, stereotype behavior, ataxia and social withdrawal. In P2X7 receptor deficient mice (*P2rx7*^{−/−}), the social interactions were increased, whereas the PCP induced hyperlocomotion and stereotype behavior were alleviated. The selective P2X7 receptor antagonist JNJ-47965567 partly replicated the effect of gene deficiency on PCP-induced behavioral changes and counteracted PCP-induced social withdrawal. We also show that PCP treatment upregulates and increases the functional responsiveness of P2X7Rs in the prefrontal cortex of young adult animals. The amplitude of NMDA evoked currents recorded from layer V pyramidal neurons of cortical slices were slightly decreased by both genetic deletion of *P2rx7* and by JNJ-47965567. PCP induced alterations in mRNA expression encoding schizophrenia-related genes, such as *NR2A*, *NR2B*, *neuregulin 1*, *NR1* and *GABA α1* subunit were absent in the PFC of young adult *P2rx7*^{−/−} animals. Our findings point to P2X7R as a potential therapeutic target in schizophrenia.

The homo-oligomeric P2X7 receptor (P2X7R) belongs to the ionotropic P2X receptors that are sensitive to ATP and other purine and pyrimidine nucleotides^{1,2}. P2X7R mediated signaling has received considerable attention in the past years as a signaling highway of immune response, cell survival and CNS pathology^{3,4}. P2X7R activation provides the co-stimulus for the posttranslational processing of the pro-inflammatory cytokine IL-1β through the activation of the NLRP3 inflammasome, and also regulates neurotransmitter release and neuronal survival in the CNS⁵.

In rodent studies, both genetic deletion and pharmacological inhibition of P2X7Rs lead to an antidepressant phenotype in behavioral paradigms mimicking depressive-like behavior^{6–9}. In addition, the same manipulations attenuate amphetamine induced hyperactivity mimicking the manic pole of bipolar disorder^{7,10–12}. These findings indicate that endogenous activation of P2X7Rs contributes to behavioral changes induced by either negative or positive challenges, and the blockade of the receptor alleviates these fluctuations. Therefore P2X7Rs have been suggested as a potential target to treat mood disorders^{4,5,13}.

Emerging data also suggest that central P2X7Rs are involved in the regulation of other complex behaviors, such as cognition and social activity. Mice deficient in *P2rx7*s display spatial memory impairment in a hippocampal-dependent memory task coincidentally with a decreased induction of IL-1β and *c-fos* in the hippocampus¹⁴. However, the selective P2X7R antagonist, A-740003 interacts with acquisition, consolidation and retrieval of aversive memory, whereas habituation memory is not affected¹⁵. Further, JNJ-42253432, a brain-penetrant P2X7R antagonist increases overall social activity and social preference¹¹. Therefore, P2X7R modulation may represent an intriguing possibility for interfering with neuropsychiatric conditions characterized

¹Laboratory of Molecular Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences (IEM HAS), H-1450 Budapest, Hungary. ²János Szentágothai School of Neurosciences, Semmelweis University School of PhD Studies, Budapest, Hungary. ³Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, H-1089 Budapest, Hungary. ⁴Janssen Research & Development, LLC, Neuroscience TA, San Diego, CA 92121, USA. ⁵Department of Behavioral Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences (IEM HAS), H-1450, Budapest, Hungary. [†]Present address: Gedeon Richter Plc., Budapest, Hungary. Correspondence and requests for materials should be addressed to B.S. (email: sperlagh@koki.hu)

by cognitive and social deficit (e.g. schizophrenia, autism). Another indication for the role of P2X7R in psychoses comes from studies showing that the phenothiazine-class antipsychotic drugs are potent allosteric modulators of the human P2X7R¹⁶.

In the hippocampus, P2X7R immunoreactivity is localized to the membrane of excitatory nerve terminals synapsing onto parvalbumin positive postsynaptic GABAergic interneuron targets, and activation of P2X7Rs elicits glutamate and subsequent GABA release^{17,18}. P2X7R activation releases glutamate from cerebrocortical nerve terminals as well^{19,20}.

Morphological and functional alteration of the microcircuits in the dorsolateral prefrontal cortex (PFC) during development is thought to be a core feature of schizophrenia²¹. A prominent feature of these circuitry alterations is the reduced excitatory input to layer 3 pyramidal neurons of the PFC and subsequent NMDA receptor hypofunction, as well as the consequently reduced transmission in the parvalbumin positive GABAergic interneurons^{22,23}. The resultant decrease in GABA signaling to PFC pyramidal neurons can lead to hyperexcitability of pyramidal neurons and might contribute to reduced γ -oscillations and subsequent impairment of working memory performance in schizophrenic patients. Therefore, molecular signaling entities targeting relatively selectively NMDA receptor hypofunction and its consequences could alleviate the symptoms of schizophrenia.

NMDA receptor hypofunction is mimicked by the psychostimulant phencyclidine (PCP) in animal experiments, which reproduce both positive and negative symptoms of schizophrenia²⁴. Because it is known P2X7R activation influences cortical glutamatergic transmission, it was worthwhile to examine the role of this receptor in PCP induced schizophrenia model in mice. In addition to behavioral changes, as a potential mediator of P2X7R induced changes, glutamatergic transmission was examined in acute prefrontal cortical slices. Finally, gene expression changes were also mapped in the hippocampus and prefrontal cortex in juvenile and young adult animals.

Results

Effect of genetic deletion and pharmacological inhibition of P2X7R on PCP induced behavioral alterations.

At first, we examined, how P2rx7 gene deficiency affect PCP induced changes in behavior (Fig. 1a). P2rx7+/+ and P2rx7−/− mice were treated with two different doses of PCP (2 or 5 mg/kg i.p.) or its vehicle (saline, SAL) and different aspects of behavior analyzed offline during a 10 min trial period applied 45 min after the PCP/SAL treatment (Fig. 1a). PCP treatment significantly affected all four aspects of behavior, i.e. locomotion, stereotypy, ataxia, and social interactions (H(5, n = 95)) values were 37.47, 77.09, 78.58, and 32.03, respectively; $p < 0.0001$ in all cases). Basal levels of locomotion, stereotypy and ataxia were not affected by genotype, but the duration of social interactions was significantly higher in P2rx7−/− as compared with P2rx7+/+ controls. In controls, PCP exerted its well-known effects: increased locomotion, stereotypy and ataxia, and decreased social interactions. The effect was dose dependent in the case of stereotypy and ataxia, and biphasic in the case of the other two variables. The decrease of locomotion at the higher dose of PCP was due to the parallel increase in ataxia and stereotypy, which prevented mice from covering large distances. Social interactions on their turn were normalized by the increase in circling behavior, the typical stereotypic behavior displayed at 5 mg/kg PCP (stereotypy score 4). Mice often circled close to each other, for which their noses often touched the body of their partners; moreover, they sniffed at each other briefly. The effects of PCP were milder in the P2rx7−/− genotype. The lower dose did not increase locomotion (Fig. 1b); albeit the higher dose decreased it, this was due to high ataxia scores, which were not affected by gene disruption (Fig. 1d). The 2 mg/kg dose did not increase stereotypy significantly, whereas the larger dose induced a smaller increase than in wild-types (Fig. 1c). The effects of PCP on social interactions were similar in the two genotypes, except that higher values were observed overall in knockouts (Fig. 1e).

Next, we have attempted to replicate findings obtained with P2rx7 gene deficient mice by systemic treatment with the selective, brain permeable P2X7 receptor antagonist JNJ-47965567 (Bhattacharya *et al.*¹⁰), which was administered as a single i.p. treatment at a 30 mg/kg dose 30 min prior to PCP regimen (Fig. 2a). Again the typical effects of PCP were observed (H(5, n = 74)) values were 32.26, 53.20, 51.01, and 28.34 for locomotion, stereotypy, ataxia, and social interactions, respectively; $p < 0.0001$ in all cases). There was no effect of the vehicle on PCP-induced behavioral changes; in-fact the vehicle + PCP group in this study was similar to P2rx7+/+ controls from the previous experiment shown in Fig. 1. (Figure 2b–e). The antagonist per se (i.e. without PCP) had no significant effect on any of the behaviors; by contrast, the effects of the lower dose (1.5 mg/kg) of PCP were abolished except for ataxia: locomotion, stereotypy and social behaviors were not affected by the low dose of PCP in mice pre-treated with JNJ-47965567 (Fig. 2b,c,e). JNJ-47965567 failed to modulate any of the behaviors manifested by high dose (5 mg/kg) of PCP.

Developmental changes of P2rx7 mRNA expression in the mouse prefrontal cortex and hippocampus.

In the next set of experiments, real-time PCR analysis was used to measure the relative P2X7 receptor mRNA levels in four age groups of naïve P2rx7+/+ mice (4, 18, 35 and 56 days) in order to reveal any developmental regulation of its expression in two brain regions implicated in PCP-induced behavioral changes, i.e. the prefrontal cortex and hippocampus. Data were normalized to the group of 4 days old mice (Fig. 3a,b). There was no statistical significant difference among the distinct age groups in prefrontal cortex tissues (Fig. 3a). In contrast, the P2X7 receptor mRNA levels in hippocampal tissues was significantly decreased in the group of 18 days old mice (0.72 ± 0.09) compared to the group of 4 days old mice (1.00 ± 0.09 , $n = 6-8$, $p < 0.05$). This decline is normalized during the adolescence and P2rx7 mRNA levels detected in 56 days old, young adult animals were similar to the 4-days old group (0.957 ± 0.05 , $n = 7$) (Fig. 3b).

Effect of PCP on P2rx7 mRNA expression in the mouse prefrontal cortex and hippocampus.

Next, we have addressed the question, whether PCP treatment induce any change of P2rx7 mRNA

Figure 1. Effect of P2rx7 gene deficiency on PCP-induced behavioral changes in mice. (a) Drug and test naïve C57Bl/6J P2rx7+/+ and P2rx7-/- mice were injected with PCP (2 or 5 mg/kg i.p.) or saline and behavior were recorded 45 min later, during a 10 min test period, as described in the methods. (b–e) Different aspects of PCP induced behavioral changes, i.e. hyperlocomotion, stereotype behavior, ataxia and the time of social interactions were quantified offline by an experimenter blind to the treatments. Asterisks indicate significant changes between genotypes or vs. saline treated group, as indicated (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). Data were analyzed by Kruskal-Wallis ANOVA. $n = 10$ –14/group.

expression in the prefrontal cortex and hippocampus. Discrepancies in relative mRNA expression levels of P2X7 receptor were also investigated in prefrontal cortex and hippocampus samples of naïve, young adult (56 days) P2rx7+/+ mice after three distinct treatments, i.e. sterile saline (0.9% NaCl) or PCP in two different dosages (2 or 5 mg/kg) (Fig. 3c). All data of normalized P2rx7 gene expression levels were compared to the group of prefrontal cortex after saline injection (1.00 ± 0.10). PCP treatment elicited region- and dose-related alterations in P2X7 receptor mRNA expression in each brain regions. In the prefrontal cortex, the lower, 2 mg/kg dose of PCP slightly elevated (1.29 ± 0.05 , $p = 0.07$) P2X7 receptor mRNA level, whilst the higher, 5 mg/kg dose did not change the expression (0.89 ± 0.08 , $n = 3$, $p > 0.05$). In contrast, in the hippocampus, 5 mg/kg dose of PCP lead to statistically significant upregulation (2.19 ± 0.1) in the gene expression level of P2rx7 compared to saline (1.57 ± 0.15 , $n = 4$, $p < 0.01$), whereas the 2 mg/kg dose of PCP was without effect (1.46 ± 0.13 , $n = 6$, $p > 0.05$). Interestingly, in saline treated groups (PFC: 1.00 ± 0.10 , HPC: 1.57 ± 0.15 , $n = 5$ –7, $p < 0.01$), and in the groups treated by the higher PCP dosage (PFC: 0.89 ± 0.08 , HPC: 2.19 ± 0.14 , $n = 3$ –4, $p < 0.001$) hippocampal P2X7 receptor mRNA level was significantly higher than in the prefrontal cortex.

P2X7R mediated [3 H]glutamate ([3 H]Glu) release is upregulated after PCP treatment in the prefrontal cortex. Because the lower dose of PCP treatment (2 mg/kg i.p.) upregulated P2rx7 mRNA expression in the prefrontal cortex, it was worthwhile to examine, whether functional responsiveness of P2X7 receptors are also subject to regulation by PCP in this brain region. P2X7 receptor activation is known to release glutamate from cortical nerve terminals, therefore, glutamate efflux induced by the P2X7 preferring agonist BzATP from

Figure 2. Effect of the selective P2X7R antagonist JNJ-47965567 (30 mg/kg i.p.) on PCP-induced behavioral changes in mice. (a) Drug and test naïve C57Bl/6J P2rx7+/+ and P2rx7−/− mice were injected with JNJ-47965567 (30 mg/kg i.p.) or its vehicle 30 min prior to subsequent PCP (1.5 or 5 mg/kg i.p.)/saline injections. Behavior was recorded 45 min later, during a 10 min test period, as described in the methods. (b–e) Different aspects of PCP induced behavioral changes, i.e. hyperlocomotion, stereotype behavior, ataxia and the time of social interactions were quantified offline by an experimenter blind to the treatments. Symbols indicate significant changes (***p < 0.001 vs. SAL, ###p < 0.001, vs. VEH). Data were analyzed by Kruskal-Wallis ANOVA. n = 10–12/group.

acute prefrontal cortex slices was used as a probe of P2X7R activation and its effect was compared to that of electrical field stimulation (EFS) in *ex vivo* saline and PCP treated wild-type and P2rx7 deficient animals, respectively. After loading the prefrontocortical slices with [³H]Glu and 90 min preperfusion, the uptake of radioactivity was 513.9 ± 28.9 kBq/g (n = 8) in saline treated P2rx7+/+ mice, and 857.9 ± 10.06 kBq/g (n = 12, p < 0.05) in the P2rx7−/− mice. The basal efflux of [³H]Glu, was 1.58 ± 0.06% (n = 8) and 1.26 ± 0.05% (n = 12, p > 0.05) in P2rx7+/+ and P2rx7−/− mice, respectively, not significantly different from each other. A 3-min perfusion with the P2X7R agonist, BzATP (100 μM) elicited a transient elevation in the efflux of [³H]Glu in P2rx7+/+ mice, which was reversible upon washout (Fig. 4a). No increase in tritium efflux was detected in response to P2X7R agonist in the slices of P2rx7−/− mice (Fig. 4a). When the slices (wild-type and knockout) were treated with PCP for 60 min, there was enhanced release of [³H]Glu as shown in Fig. 4a. Preceding PCP treatment did not change radioactivity uptake into the slices in P2rx7+/+ mice (363.33 ± 86.5 kBq/g, n = 8, p > 0.05 vs. SAL). The basal release was higher in P2rx7+/+ slices than in P2rx7−/− slices. BzATP induced tritium efflux was enhanced after PCP treatment in P2rx7+/+ mice (evoked release: 1.5 ± 0.33%, n = 8 and 4.18 ± 0.91% in saline and PCP treated mice, n = 8 each, p < 0.05 (Fig. 4a)).

Electrical field stimulation also elicited reversible [³H]Glu efflux in P2rx7+/+ mice, which was not decreased in P2rx7 deficient mice (Fig. 4b). EFS induced [³H]Glu efflux was also enhanced by PCP in P2rx7+/+ animals (Fig. 4b, evoked release: 1.5 ± 0.57% and 7.42 ± 1.39% in saline and PCP treated mice, n = 8 each, p < 0.01). EFS

P2rx7 mRNA

Figure 3. Age-dependence and effect of PCP on P2rx7 mRNA expression in the prefrontal cortex and hippocampus. Developmental changes of P2rx7 relative mRNA expression in prefrontal cortex (a) and hippocampus (b) of naïve C57Bl/6J P2rx7+/+ mice of four age groups (4, 18, 35 and 56 days). Gene expression levels of P2rx7 were normalized to the gene expression level of Gapdh, as the endogenous control gene. The normalized P2rx7 mRNA expression levels of 4 days old animals were interpreted as 100% to compare the P2rx7 gene expression level in distinct age groups. Data are displayed as the mean $\pm$ S.E.M. (* $p < 0.05$, one-way ANOVA followed by Fisher's LSD post hoc test). $n = 6-8$ /group. (c) Effect of PCP on P2rx7 mRNA expression levels in the mouse prefrontal cortex and hippocampus. Young adult (56 days old) animals were given an intraperitoneal (i.p.) injection of sterile saline (0.9% NaCl) or PCP in two distinct doses (2 and 5 mg/kg). Gene expression levels of P2rx7 were normalized to the gene expression level of Gapdh, as the endogenous control gene. The normalized P2rx7 mRNA expression level in the PFC of the saline-treated group was interpreted as 100%. Data are displayed as the mean $\pm$ S.E.M. (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; two-way ANOVA followed by Fisher's LSD post hoc test). $n = 3-6$ /group. Illustrations of coronal section 21 and horizontal section 4 of the mouse brain are originated from the website of <http://www.mbl.org> (PFC and HPC regions are highlighted)⁶⁹.

increased Glu efflux in PCP-treated P2X7 $^{-/-}$ mice, when compared to baseline (Fig. 4b). However, the net EFS evoked Glu efflux in these animals was not significantly different from saline treated P2rx7 $^{-/-}$ animals (Fig. 4b, evoked release: $4.73 \pm 1.0\%$, $n = 12$ and $5.72 \pm 2.38\%$, $n = 8$, in saline and PCP treated mice, $p > 0.05$).

To explore any effect on dopaminergic transmission [3 H]dopamine ([3 H]DA) release experiments were also performed. In these experiments, the radioactivity uptake was 251.144 ± 17.429 kBq/g and 279.789 ± 20.905 kBq/g, ($n = 14$; 6, $p > 0.05$), whereas the resting [3 H]DA efflux was $1.23 \pm 0.05\%$ and $0.99 \pm 0.03\%$ in P2rx7+/+ and P2rx7 $^{-/-}$ mice, respectively ($p < 0.001$). Perfusion of the slices with ATP (10 mM) elicited a transient elevation of tritium efflux, but this was not affected by the genetic deletion of P2X7 receptors (evoked release: $1.24 \pm 0.22\%$, $n = 12$ and $1.01 \pm 0.12\%$, $n = 6$, in P2rx7+/+ and P2rx7 $^{-/-}$ mice, $p > 0.05$).

Effect of genetic deletion and pharmacological inhibition of P2X7R on NMDA induced currents recorded from the mouse prefrontal cortex. The previous experiments clarified that PCP treatment upregulates mRNA level and increase the functional responsiveness of P2X7 receptors in the prefrontal cortex, resulting in a higher elevation of glutamate efflux. Next, we examined, whether endogenous P2X7 receptor activation alter the responsiveness of prefrontocortical NMDA-type glutamate receptors using the whole cell patch clamp technique. Application of various concentrations (1–1000 μ M) of NMDA to layer V pyramidal cells of prefrontal cortex induced inward current responses both in P2rx7+/+ and P2rx7 $^{-/-}$ mice ($n = 5-16$ at different concentrations). It is noteworthy, that the pyramidal cells mostly showed large biological variability in sensitivity to NMDA making difficult the statistical analysis.

Figure 4. Modulation of the glutamatergic transmission in the mouse prefrontal cortex by P2X7 receptors. Effect of lower dose of PCP treatment (2 mg/kg i.p.) on P2X7R mediated (a) and electrically evoked (b) $[^3\text{H}]$ glutamate release from the *ex vivo* acute PFC slices. C57Bl/6J P2rx7+/+ and P2rx7−/− mice were injected with PCP (2 mg/kg i.p.) or saline and acute PFC slices were prepared 60 min later and incubated with $[^3\text{H}]$ glutamate (see Methods). During the sample collection period, slices were stimulated by the P2X7R agonist BzATP (100 μ M) or electrical field stimulation (EFS), as indicated by the horizontal bars. Data are displayed as the mean $\pm$ S.E.M. $n = 8$ –12/group. (c) Concentration-response curves of NMDA in P2rx7+/+ mice in the presence or in the absence of the P2X7R antagonist JNJ-47965567 (100 nM, JNJ) as well as in P2rx7−/− mice. NMDA (1–1000 μ M) was applied in increasing concentrations and the amplitude of the NMDA evoked inward currents were recorded from layer V pyramidal neurons of cortical slices. Concentration-response curves for NMDA were fitted using the logistic function of SigmaPlot (Systat). Data are displayed as the mean $\pm$ S.E.M. of $n = 5$ –16 cells at different NMDA concentrations (* $p < 0.05$; P2rx7−/− vs. P2rx7+/+; two-way ANOVA). Illustration of horizontal section 4 of the mouse brain is originated from the website of <http://www.mbl.org> (PFC region is highlighted)⁶⁹.

At low NMDA concentrations (1–10 μ M) notable difference between the responses to NMDA in cells derived either from P2rx7+/+ or from P2rx7−/− mice could not be observed (Fig. 4c). However, when higher agonist concentration was applied (30 μ M NMDA), a significant difference was revealed in the amplitude of the NMDA currents, i.e. the responses were larger in wild-type animals (2658 ± 504 pA) compared with those lacking P2X7 receptors (1343 ± 238 pA). The concentration-response curves indicated similar tendency at still higher NMDA concentrations resulting in higher E_{max} value of the curve in wild-type mice compared with the P2rx7−/− animals (4330 ± 1171 pA vs 3224 ± 693 pA). Other major parameters of the concentration-response curves (EC_{50} : 24.98 ± 0.27 vs. 41.78 ± 0.26 ; Hill coefficient: 0.91 ± 0.58 vs. 0.85 ± 0.57 ; wild type vs. P2rx7−/− mice, respectively) did not display any remarkable difference.

Subsequently, the NMDA concentration-response relationship was also investigated in layer V pyramidal cells of the wild-type mice in the presence of the P2X7 antagonist JNJ-47965567 (0.1 μ M). As Fig. 4c shows, the pharmacological blockade of the P2X7 receptors apparently had similar influence on the curve like the genetic deletion of the receptor. The main observation is that the E_{max} of the curve in the presence of the P2X7 antagonist

was reduced (2831 ± 360 pA) compared with the curve in the absence of the antagonist (see above). However, the clear tendency did not result in a statistically significant difference.

Genetic deletion of P2rx7 causes region specific changes in the expression of glutamate and GABA receptor subunits and schizophrenia related genes. Alterations in gene expression might accompany, or convey long term adaptive changes in behavior and it is known that genetic deficiency of P2X7R have a strong impact on the mRNA expression of a number of genes showing biological plausibility in psychiatric disorders⁷. In the next part of the study we have examined, whether gene expression changes driven by PCP are also subject to regulation by P2X7 receptors. At first, mRNA expression levels of a set of genes encoding ionotropic NMDA (Grin1, Grin2a, Grin2b) and metabotropic (Grm3) glutamate receptors, were examined in prefrontal cortex samples derived from juvenile (18 days old) and young adult (56 days old), P2rx7+/+ and P2rx7-/- mice treated by saline (0.9% NaCl) or PCP (dose of 2 mg/kg) 1 h after the PCP injection. Gene expression was compared to the data found in saline treated, juvenile P2rx7+/+ mice. Whereas we could not detect significant change in mRNA level of these genes in response to either PCP treatment or genotype in the juvenile animals, their expression pattern was substantially altered in the young adult, P2rx7+/+ mice (Fig. 5). Among the NMDA type glutamate receptor subunits, the relative gene expression levels of Grin1 was significantly decreased in PCP treated mice, when compared to saline treated group (Fig. 5a). Although a tendency can be observed, this change did not reach the level of significance in P2rx7-/- mice (Fig. 5a). Interestingly, Grin1 mRNA expression was lower in P2rx7-/- mice, when compared to wild-type counterparts either in the saline and PCP treated groups (Fig. 5a).

As for Grin2a and Grin2b, PCP treatment upregulated their expression in young adult P2rx7+/+ mice (Fig. 5b,c). Once again, these changes were not detected in mice genetically deficient in P2rx7 (Fig. 5b), and turned to into a significant downregulation in case of Grin2b (Fig. 5c). Grin2a and Grin2b levels were also significantly lower in PCP treated P2rx7-/- mice, when compared to PCP treated P2rx7+/+ mice (Fig. 5b,c),

Figure 6. Effect of the higher dose of PCP (5 mg/kg) on the relative mRNA expression levels of ionotropic NMDA (a) Grin1, (b) Grin2a, (c) Grin2b and a metabotropic glutamate receptor, (d) Grm3. Samples are derived from HPC of juvenile (18 days old) and young adult (58–60 days old), P2rx7+/+ and P2rx7−/− mice. Gene expression levels of each gene were normalized to the gene expression level of Gapdh. Normalized mRNA expression levels in juvenile saline-treated P2rx7+/+ animals were interpreted as 100%. Data are displayed as the mean ± S.E.M. (* $p < 0.05$, ** $p < 0.01$; two-way ANOVA followed by Fisher's LSD post hoc test). $n = 3–4$ /group. Illustration of coronal section 21 of the mouse brain is originated from the website of <http://www.mbl.org>, (HPC regions is highlighted)⁶⁹.

whereas in saline treated P2rx7−/− mice Grin2b was upregulated when compared to saline treated P2rx7+/+ mice (Fig. 5c).

mRNA Expression of Grm3 encoding metabotropic glutamate receptor 3 displayed a robust downregulation during adolescence resulting in values close to detection limit in young adult animals, when compared to the juvenile group (Fig. 5d). Therefore data of these groups were also normalized to values of the saline treated, young adult P2rx7+/+ mice (Fig. 5d, inset). PCP treatment caused a significant decrease in the expression level of Grm3, and this change could be observed in the absence of P2X7R as well (Fig. 5d, inset). Genotype did not affect the expression of Grm3 in either groups (Fig. 5d).

Because the higher dose of PCP upregulated P2rx7 mRNA in the hippocampus, next we assessed how the expression of the above four genes are altered by genotype and the higher dose of PCP (5 mg/kg i.p.) in the hippocampus of juvenile and young adult mice (Fig. 6). When compared to PFC, changes in the expression of genes were relatively mild in the hippocampus. There was no significant change in Grin1 expression by PCP treatment in juvenile and young adult mice of either genotype (Fig. 6a) and the same holds true for Grin2b (Fig. 6c). A slight, but significant upregulation of Grin2a could be observed in young adult P2rx7+/+ mice, and this change was not detected in P2rx7−/− mice (Fig. 6b). In contrast, Grm3 was slightly downregulated by PCP in young adult P2rx7+/+ mice and this effect also disappeared in age-matched P2rx7−/− mice (Fig. 6d).

Next, we extended gene expression profiling studies to a further selection of genes showing biological plausibility for schizophrenia (Fig. 7). These genes were the following: D1 and D2 dopamine receptors (Drd1, Drd2), catechol-o-methyltransferase (Comt), Neuregulin 1 (Nrg1), metabotropic glutamate receptor subtype 2 and 5 (Grm2, Grm5), GABA_A receptor subunit $\alpha 1$ and $\alpha 5$ (Gabra1 and Gabra5). Because the previous experiments showed that gene expression changes by PCP treatment and genotype were more pronounced in the PFC and in the young adult animals, PCP (2 mg/kg i.p.) and genotype induced changes were analyzed in the PFC in this age group. The following alterations were found: a profound upregulation of Neuregulin1 (Nrg1) mRNA expression was found in response to PCP treatment which was absent in P2X7 receptor deficient animals (Fig. 7a). A downregulation of D2 receptor mRNA (Drd2) by PCP was also observed in P2rx7+/+ mice; however this change was persisted in P2rx7−/− mice (Fig. 7b). Likewise, a PCP induced downregulation of metabotropic glutamate receptor subtype 2 (Grm2) was found in the prefrontal cortices of both P2rx7+/+ and P2rx7−/− mice (Fig. 7c). In contrast, PCP treatment significantly decreased the mRNA expression of metabotropic glutamate receptor

Figure 7. Effect of the lower dose of PCP (2 mg/kg) on the relative mRNA expression levels of selected, schizophrenia related genes, (a) *Nrg1*, (b) *Drd2*, (c) *Grm2*, (d) *Grm5*, (e) *Gabra1*. Samples are derived from PFC of young adult (56 days old), P2rx7+/+ and P2rx7-/- mice. Gene expression levels of each genes were normalized to the gene expression level of *Gapdh*. Normalized mRNA expression levels in saline-treated P2rx7+/+ animals were interpreted as 100%. Data are displayed as the mean $\pm$ S.E.M. (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; two-way ANOVA followed by Fisher's LSD post hoc test). $n = 3-6$ /group. Illustration of horizontal section 4 of the mouse brain is originated from the website of <http://www.mbl.org>, (PFC region is highlighted)⁶⁹.

subtype 5 (*Grm5*, (Fig. 7d)) and GABA_A receptor subunit $\alpha 1$ (*Gabra1*, (Fig. 7e)) and these changes were eliminated in the absence of P2X7R. mRNA expression of *Grm2*, *Grm5* and *Gabra1* was significantly lower in saline treated P2rx7-/- mice when compared to saline treated P2rx7+/+ mice (Fig. 7c-e). No change in D1 dopamine (*Drd1*), catechol-o-methyltransferase (*Comt*) and GABA_A receptor subunit $\alpha 5$ (*Gabra5*) was detected by either PCP or genotype (data not shown).

Discussion

Schizophrenia is a multidimensional disorder characterized by positive, negative and cognitive symptoms involving a multiplicity of neurotransmitters and signaling pathways. The potential role of purinergic signaling system in schizophrenia has been raised by several studies¹³; however so far only the involvement of A_{2A} adenosine²⁵ and P2Y₁ receptors²⁶ have been tested in experimental disease models, respectively.

PCP, as an NMDA-type glutamate receptor antagonist evokes schizophrenia-like symptoms in human²⁷, and its application in rodents is a widely applied and reliable pharmacological model to investigate the disease pathophysiology and to test potential new treatments^{28,29}. PCP-induced schizophrenia models mimic a wide facet of symptoms including positive, negative and cognitive symptoms and the paradigm used in our study replicated the expected behavioral alterations described previously²⁴.

The principal new finding of the present study is that both genetic deletion and pharmacological blockade of P2X7Rs lead to significant alterations in behavior induced by PCP in mice and suggesting that these receptors are endogenously activated in this model. Whereas PCP induced hyperlocomotion and stereotype behavior were alleviated by both genetic deletion and pharmacological inhibition of P2X7Rs the basal level of social interactions were increased in P2rx7^{-/-} mice but not by JNJ-47965567 suggesting a developmental effect of genetic deletion. In this respect our findings differ from a previous observation using another brain permeable P2X7R antagonist, JNJ-42253432, which increased social interactions and social preference irrespectively from prior stress exposure in rats¹¹. The reason for this discrepancy could be slight differences in experimental protocol, species variance or the distinct affinities of the two P2X7R antagonists to splice variants of P2rx7, responsible for this particular effect^{30,31}. Nevertheless, JNJ-47965567 restored social withdrawal elicited by PCP.

It is well known that P2X7R activation leads to increased glutamate release from the hippocampal slices^{8,17} and from cerebrocortical nerve terminals¹⁹. Here we extend these results demonstrating P2X7R-mediated glutamate release from acute PFC slices. Moreover, we show that P2X7R mediated glutamate release is upregulated in response to PCP treatment, which could be a consequence of increased expression of P2X7Rs detected in mRNA expression studies. A similar functional upregulation of P2X7R mediated glutamate release were detected in response to *in vitro* ischemia-like conditions³² and recently using oxaliplatin induced neuropathic pain model in the cerebral cortex³³. Because we used acute slices, with an intact neuron-glia network, P2X7R mediated glutamate release could be originated either from nerve terminals or from the neighboring astrocytes as demonstrated in electrophysiological studies³⁴. Moreover, glutamate released by P2X7R activation might also act on either neuronal or glial NMDA receptors. However, in a previous study P2rx7 gene deficiency did not affect NMDA evoked currents recorded from *in situ* cortical astroglia³⁵. In the present study, the current amplitude of NMDA mediated currents from layer V pyramidal neurons was slightly alleviated by both genetic deletion and pharmacological blockade of P2X7R (Fig. 4c). Bath-applied NMDA induced currents in whole-cell patch clamp experiments are predominantly caused by direct activation of postsynaptic receptors by external NMDA. Therefore, our findings suggest that prefrontocortical postsynaptic NMDA receptors are under the regulation of P2X7Rs at least in juvenile animals. However, the pyramidal neurons were not isolated synaptically in our patch clamp experiments, therefore contribution of presynaptic mechanisms to the observed effect involving presynaptic NMDA receptors cannot be unequivocally excluded. Although both genetic deficiency and pharmacological blockade of P2X7R reduced the current amplitude evoked by 30 μ M NMDA, and the concentration-response curves showed a strong tendency of flattening, these effects were not too robust, which is also compatible with an indirect effect (Fig. 8).

The peak ATP concentration in the synaptic cleft is estimated as high as several hundreds of micromole under neuronal activity³⁶. Recently, two studies detected extracellular ATP in a behaviorally relevant concentration in the prefrontal cortex *in vivo*^{9,37}. These findings explain how PFC P2X7Rs could be endogenously activated under the experimental conditions of behavior experiments.

As for gene expression changes, a prominent increase in the relative Grin2b (NR2B) mRNA expression level was detected after PCP treatment, in the PFC of young adult, but not juvenile P2rx7^{+/+} mice (Fig. 5c). These data are consistent with the elevation of NR2B protein expression to acute PCP treatment in the frontal cortex of the rat brain³⁸, and with human post mortem studies, founding increased NR2B subunit mRNA and protein levels in cortical areas of schizophrenic patients^{27,39,40}, but see ref. 41. *In vivo* treatment with NR2B receptor antagonists reproduce some features of schizophrenia-like behavior, such as hyperlocomotion and impaired PPI in rodents^{42–45}, just like the cortical genetic deletion of NR2B in mice⁴⁶, pointing to the determinant role of this subunit of NMDA receptor in shaping of the schizophrenia-like behavioral changes.

However, earlier studies showed that NMDA receptor antagonist treatment leads to the loss of parvalbumin and GAD67 in cortical areas with the involvement of NR2A subunit of the receptor⁴⁷. In our study, Grin2a (NR2A) subunit mRNA expression level was also higher in the PFC of PCP treated young adult P2rx7^{+/+} mice (Fig. 5b). Collectively, these observations suggest that PCP induced NR2A and NR2B upregulation found in the PFC of young adult rats are compensatory changes due to NMDA receptor hypofunction elicited by PCP treatment. Importantly, PCP induced changes in mRNA expression level of NR2A and NR2B subunits were not detected in P2rx7^{-/-} mice indicating that the effect of PCP on NMDA receptor subunit expression is mediated or modulated by endogenous P2X7R activation.

As for other schizophrenia related genes, an elevated Nrg1 gene expression level was found in the present study in PFC of young adult P2rx7^{+/+} animals after PCP treatment (Fig. 7a). There is rather strong evidence that one of the major susceptibility genes for schizophrenia is Neuregulin 1 protein coding gene (NRG1) that might be responsible for a fraction of schizophrenia cases^{27,48,49}. In line with our results, upregulation of NRG1 type 1 mRNA and protein was detected in post-mortem dorsolateral PFC tissues derived from schizophrenic patients^{50–52}. Schizophrenic-like phenotype is also detected in heterozygous TM-domain NRG1 mutant mice⁵³.

NRG1 signaling has a prominent role in early neural development. NRG1 acts predominantly through the ErbB4 tyrosine kinase receptor and may alter the NMDA receptor levels and their function, by phosphorylation of NR2 subunits of the receptor⁵⁴. However, it is also possible that primary dysfunction of other genes and signaling molecules, leads to the secondary alteration of NRG1 expression and functioning in schizophrenia. Supporting this latter theory and our data Feng *et al.* found that the NMDA receptor antagonist MK801 upregulated NRG1 protein in the PFC of adult rats⁵⁵. Perinatal PCP treatment also caused similar changes increasing NRG1 protein expression in the PFC of adult, but not adolescent rats^{56,57}. Once again, PCP-induced upregulation of NRG1 mRNA in the PFC was not detected in P2rx7^{-/-} mice suggesting the specific interaction between P2X7R mediated signaling and NRG1-signaling, possibly indirectly, with the involvement of glutamatergic transmission.

According to current hypotheses, PCP induced NMDA receptor hypofunction leads to a deficit of parvalbumin positive GABAergic interneurons and the consequent cortical disinhibition is responsible for schizophrenia specific symptoms^{58–60}. Accordingly, significant decrease in the gene expression level of GABA_A receptor subunit $\alpha 1$ was observed after the lower dose of PCP treatment in our experiments, in the PFC of young adult, P2rx7^{+/+}

Figure 8. The hypothesis for the potential interactions of the P2X7 receptor with NMDA receptor regulation. (a) The stimulation of P2X7Rs by ATP/BzATP increased the release of glutamate in the prefrontal cortex, which could be derived from nerve terminals or astrocytes. This release of glutamate and NMDA-receptor mediated currents were decreased in the absence or under the pharmacological blockade of P2X7 receptors. These data imply that postsynaptic NMDA receptors are subject to modulation by P2X7 receptors directly or indirectly. (b) The NMDA receptor antagonist, phencyclidine (PCP) evokes schizophrenia-like behavior, through the disinhibition of parvalbumin (PV) containing GABAergic neurons synapsing onto prefrontocortical pyramidal neurons, resulting in increased EFS-induced glutamate efflux detected in release experiments. In parallel with behavioral changes, the mRNA expression of Neuregulin 1 (Nrg1), different NMDA receptor subunits (Grin1, Grin2a, Grin2b), the GABA_A Receptor $\alpha 1$ Subunit (Gabra1) and the metabotropic glutamate receptor 5 (Grm5) are also dysregulated, and all these alterations are subject to regulation by P2X7 receptors. In turn, PCP treatment upregulates and increases the functional responsiveness of P2X7 receptors, resulting in an increased BzATP-induced glutamate efflux. Figure 8 was created by modifying images purchased in the PPT Drawing Toolkits-BIOLOGY Bundle from Motifolio, Inc (<http://www.motifolio.com/neuroscience.html>).

mice and this change was also eliminated in P2rx7^{-/-} mice (Fig. 7e). Likewise, significant reduction in GABA_A receptor subunit $\alpha 1$ mRNA level was observed in cerebral cortices and hippocampus after a single PCP injection in rats⁶¹.

In contrast to glutamatergic signaling, PCP induced downregulation of D2 receptors and [³H]dopamine release from the PFC were not subject to modulation by P2X7 receptors.

P2X7R antagonists have been proposed as a potential drug target in a variety of inflammatory and CNS diseases^{3,4}. Although first clinical trials with P2X7R antagonists have not proven their efficacy in systemic inflammatory disorders⁶², recent trials proved to be more promising in terms of efficacy and all those compounds, which entered to clinical trials displayed a beneficial risk profile⁶³. Moreover, in the past years various classes of small molecule, drug-like P2X7R inhibitors have been developed, which readily enter the brain and display high degree of target engagement in the CNS^{64,65}. Although further studies should elucidate the role of P2X7R in cortical development and its contribution to schizophrenia endophenotype, our findings points to its role as a potential target in schizophrenia.

Materials and Methods

Animals. All studies were conducted in accordance with the principles and procedures outlined in the NIH Guide for the Care and Use of Laboratory Animals and were approved by the local Animal Care Committee of the Institute of Experimental Medicine (Budapest, Hungary, ref. No. PEI/001/778–6/2015). Young adult, 2–3 month old drug and test naïve male wild-type (P2rx7+/+) and P2X7 receptor knockout (P2rx7–/–) mice were housed in a light- (12 h on, 12 h off) and temperature-controlled room with food and water available ad libitum. All experiments were performed during the light phase between 7:30 am and 3:30 pm. Homozygous P2X7 receptor P2rx7+/+ mice were bred on a background of C57Bl/6J. The original breeding pairs of P2rx7–/– mice were kindly supplied by Christopher Gabel from Pfizer, Inc. (Groton CT, USA). The animals contained the DNA construct P2X7-F1 (5'-CGGCGTGCGTTTGGACATCCT-3') and P2X7-R2 (5'-AGGGCCCTGCGGTTCTC-3'), previously shown to delete the P2X7 receptor⁶⁶. Offspring of this mouse line were cross-bred with P2rx7+/+ mice, and the resulting heterozygotes were used as breeding stock for the F1 generation offspring employed in the behavior studies. Genomic DNA was isolated from the tails of P2rx7+/+ and P2rx7–/– animals, and the genotypes were confirmed by PCR analysis.

Behavior studies. Animals were randomly assigned to different treatment groups with a sample size of 10–12 and six groups/experiment were formed (2 genotypes/pharmacological treatment, 2 doses of PCP + vehicle). Mice were subjected to single i.p. treatment with the selective P2X7 receptor antagonist JNJ-47965567 (30 mg/kg i.p., donated by Janssen Research & Development, San Diego, USA) or its vehicle (30% β -cyclodextrin, Cydex Pharmaceuticals, Lawrence, USA). 30 min after the treatment, mice were injected i.p. with different doses of phencyclidine (PCP, 1.5–2–5 mg/kg Sigma-Aldrich Kft, Budapest) or its vehicle (saline, 0.9% NaCl) in a 10 ml/kg injection volume. The actual dose selection for the lower dose of PCP (2 vs. 1.5 mg/kg) was based on the evaluation of preliminary experiments and behaviorally equipotent doses were administered in the two series of experiment. Forty-five minutes later, mice were submitted to the social withdrawal test, according to the method of Sams-Dodd^{67,68}. The test was performed in a dark-grey, circular open field. Two unfamiliar mice receiving the same pharmacological treatment were placed into the open field. Mice were placed at opposite sides of the apparatus. Behavior was recorded for 10 min by means of a video camera placed above the open field.

An experimenter blind to the treatments scored all behaviors on video recordings. An independent experimenter checked scoring and reliability, which was usually above 90%. The following behavioral variables were recorded: distance travelled, stereotype behavior, ataxia and social investigation. Phencyclidine-induced stereotyped behavior and ataxia were scored according to the protocol described in⁶⁷. Social investigations were defined as sniffing directed towards the partner, when the nose of the scored mouse touched (or was very close to) the body of the partner. Line crossings and social interactions were recorded for the whole duration of the test by means of a computer-based event recorder.

[³H]Glutamate ([³H]Glu)/[³H]dopamine ([³H]DA) release experiments. Experiments were performed on young adult (2–3 months) male wild-type (P2rx7+/+) and P2X7 receptor knockout (P2rx7–/–) mice, subjected to saline or PCP (2 mg/kg i.p.) treatment 60 min before the experiment. The [³H]Glu release experiments were conducted using the method with slight modifications described in our previous papers (e.g.⁸). Briefly, the mice were anaesthetized under light CO₂ inhalation, and subsequently decapitated. The prefrontal cortex was dissected in ice-cold Krebs solution saturated with 95% O₂ and 5% CO₂, sectioned (400- μ m-thick slices) using a McIlwain tissue chopper and incubated in 1 ml of modified Krebs solution (113 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl₂, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 25.0 mM NaHCO₃, and 11.5 mM glucose), pH 7.4, in the presence of 5 μ Ci/ml [³H]glutamic acid ([³H]Glu, 9.8 $\times$ 10^{–8} M, specific activity 60 Ci/mmol; ARC, Saint Louis, MO, USA) or in some experiments with [³H]dopamine ([³H]DA, specific activity 60 Ci/mmol; ARC, Saint Louis, MO, USA) for 45 min. The medium was bubbled with 95% O₂ and 5% CO₂ and maintained at 32 °C ([³H]DA: 37 °C). After loading, the slices were continuously superfused with 95% O₂ and 5% CO₂-saturated modified Krebs solution (flow rate: 0.7 ml/min). After a 90 min washout period to remove excess radioactivity, perfusate samples were collected over 3 min periods and assayed for tritium content. The temperature was strictly kept at room temperature (22–23 °C, [³H]DA: 37 °C). At 6 min after the start of the collection, the slices were subjected to a 3 min perfusion of the P2rx7 agonist 3'-O-(4-benzoyl-benzoyl)adenosine 5'-triphosphate, (BzATP, 100 μ M, Sigma) under Mg²⁺ free conditions and then changed to normal Krebs solution until the end of the collection period or challenged by electrical field stimulation (EFS, 10 Hz, 1 msec).

The radioactivity released from the preparations was measured using a Packard 1900 Tricarb liquid scintillation spectrometer, using Ultima Gold Scintillation cocktail. The release of tritium was expressed as a percentage of the amount of radioactivity in the tissue at the sample collection time (fractional release). The tritium uptake in the tissue was determined as the sum of release + the tissue content after the experiment and expressed in Bq/g. For the evaluation of the basal tritium outflow the fractional release measured in two consecutive 3 min samples under drug free conditions were taken into account. The BzATP/EFS-induced [³H]Glu efflux calculated as the net release in response to the respective stimulus by subtracting the release before the stimulation from the values measured after stimulation. HPLC analyses performed in previous studies (ref. 8) revealed that the majority of tritium released by P2X7R activation represents [³H]glutamate.

Electrophysiological studies. *Brain slice preparation.* Young P2rx7+/+ and P2rx7–/– mice pups (16–20 days old) were decapitated and their brains were quickly removed and submerged in ice-cold artificial cerebrospinal fluid (aCSF) saturated with 95% O₂ and 5% CO₂ of the following composition (mM): NaCl 126, KCl 2.5, NaH₂PO₄ 1.2, CaCl₂ 2.4, MgCl₂ 1.3, NaHCO₃ 25 and glucose 11; pH 7.4. Thin coronal slices (200 μ m thickness) were cut from a block of tissue containing the prelimbic portion of the medial prefrontal cortex

using a vibrating blade microtome. After being sectioned, 6–8 slices obtained from a single brain were transferred to a holding chamber and stored in oxygenated aCSF at 36 °C for 1 h, and then at room temperature (22–24 °C). Before use, single slices were transferred to a recording chamber (300–400 μ l volume) and continuously superfused (3 ml/min) with oxygenated aCSF at room temperature. The bath solution differed from aCSF used for incubation, in that Mg^{2+} was omitted. The slices were left to recover for at least 15 min before the start of individual experiments. Only one cell was measured in each brain slice.

Whole-cell patch-clamp recordings in brain slices. Pyramidal cells in layer V of the prefrontal cortex were visualized with an upright microscope equipped with a $\times 40$ water immersion objective (Axioscope FS; Carl Zeiss). Patch pipettes prepared from borosilicate glass capillaries were filled with intracellular solution of the following composition (mM): potassium gluconate 140, NaCl 10, $MgCl_2$ 1, HEPES 10, EGTA 11, Mg-ATP 1.5, Li-GTP 0.3; pH 7.3 adjusted with KOH solution. Pipette resistances were in the range of 5–7 M Ω . After establishing whole cell access, the system was left for 5–10 min to allow for the settling of diffusion equilibrium between the patch pipette and the cell interior. Current were registered at a holding potential of -70 mV, in the voltage-clamp mode of the patch-clamp amplifier (Axopatch 200B; Molecular Devices).

Different drugs were applied by changing the superfusion medium. In order to construct concentration-response curves, NMDA (1–1000 μ M) was used as an agonist. NMDA was applied for 1.5 min, in increasing concentrations, applications being separated by a superfusion period of 10 min with drug-free aCSF. When the effects of the P2X7 antagonist were investigated, it was present in the superfusion medium throughout the experiment.

Data were filtered at 2 kHz with the inbuilt filter of Axopatch 200B, digitized at 5 kHz, and stored on a laboratory computer using a Digidata 1200 interface and pClamp 10.0 software (Molecular Devices).

Gene expression analysis. To examine the age-related mRNA expression levels of P2X7 receptor in the prefrontal cortex (PFC) and hippocampus (HPC) 4, 18, 35 and 56 days old naive P2rx7+/+ mice (8 animals/group) were used. To investigate the effect of PCP on the P2X7 receptor gene expression level in young adult (56 days old) mice were given an intraperitoneal (i.p.) injection of sterile saline (0.9% NaCl) or phencyclidine (PCP, 2 and 5 mg/kg, Sigma-Aldrich Kft, Budapest). To identify genes involved in PCP-induced changes in the juvenile (18 days old) and young adult (56 days old) P2X7 receptor wild type (P2rx7+/+) and knockout (P2rx7−/−) mice we used the same treatments that were mentioned above. Approximately 1 hour after the treatment prefrontal cortex (PFC) and hippocampus (HPC) samples were collected from all animals ($n = 3$ –6 mice/group). Total RNA samples were isolated and purified from homogenate using the RNeasy Lipid Tissue Mini Kit (Qiagen) according to the manufacturer's instructions. To measure the total RNA concentration and the integrity of the RNA samples, the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) was used with Agilent RNA 6000 Nano Kit (Agilent Technologies, Palo Alto, CA). Tetro cDNA Synthesis Kit (Bioline USA Inc, Taunton, MA) was used according to the manufacturer's protocol to synthesize the first strand cDNA from the RNA samples. The relative quantification of target genes expression levels were performed by quantitative real-time PCR analysis (ViiA™ 7 Real-Time PCR System, Applied Biosystems and Life Technologies, Foster City, CA, USA).

Real-time PCR. TaqMan® Fast Universal PCR Master Mix (2 $\times$), No AmpErase® UNG with TaqMan® Gene Expression Assays (Applied Biosystems and Life Technologies, Foster City, CA, USA) were applied in real-time PCR experiments, according to the manufacturer's instructions. In comparison to the age-related mRNA expression levels of P2X7 receptor, the normalized P2rx7 mRNA expression level of 4 days old animals were interpreted as 100%. To examine the effect of PCP on the P2X7 receptor gene expression level in two different doses (2 mg/kg or 5 mg/kg), the normalized P2rx7 mRNA expression level in the PFC of the saline-treated group were interpreted as 100%. Four types of glutamate receptor gene expression levels (Grin1 (NR1), Grin2a (NR2A), Grin2b (NR2B), Grm3 (mGluR3)) were analyzed after the PCP treatment, in P2rx7+/+ and P2rx7−/−, juvenile (18 days old) and young adult (56 days old) mice PFC (PCP dose of 2 mg/kg), and HPC (PCP dose of 5 mg/kg). The gene expression levels of the juvenile, saline-treated P2rx7+/+ animals were interpreted as 100%. The effect of lower dose of PCP (2 mg/kg) on the relative mRNA expression levels of selected, schizophrenia related genes, (Nrg1, Drd2, Grm2, Grm5, Gabra1) were measured in PFC samples of young adult (56 days old), P2rx7+/+ and P2rx7−/− mice. The gene expression levels in the P2rx7+/+ and saline-treated animals were interpreted as 100%. All of the gene expression levels were normalized to the mRNA expression level of the glyceraldehyde 3-phosphate dehydrogenase (Gapdh) as an endogenous control (housekeeping gene). The list of the TaqMan® Gene Expression Assay ID of the target genes can be found as Supplementary Table S1.

Data analysis and statistics. For the statistical analysis of gene expression and behavior data, STATISTICA 64 software (StatSoft, Inc., Tulsa, OK, USA) was applied. Differences were analyzed by Kruskal–Wallis ANOVA (behavior studies) and two-way ANOVA followed by Fisher's least significant difference (LSD) post hoc test (gene expression studies). Respective data derived from release experiments were analyzed by Student t-test (pair-wise comparisons) or one-way ANOVA followed by Tukey test (multiple comparisons), as appropriate. For the electrophysiology, data were analyzed off-line using pClamp 10.0 software (Molecular Devices). Concentration-response curves for NMDA were fitted using the logistic function of SigmaPlot (Systat). Two-way ANOVA was used for statistical analysis. All data are expressed as mean $\pm$ S.E.M. (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). A probability level of 0.05 or less was considered to reflect a statistically significant difference.

References

1. Surprenant, A., Rassendren, E., Kawashima, E., North, R. a. & Buell, G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). *Science* **272**, 735–738 (1996).

2. Jarvis, M. F. & Khakh, B. S. ATP-gated P2X cation-channels. *Neuropharmacology* **56**, 208–215 (2009).
3. Sperlagh, B., Vizi, E. S., Wirkner, K. & Illes, P. P2X7 receptors in the nervous system. *Progress in Neurobiology* **78**, 327–346 (2006).
4. Sperlagh, B. & Illes, P. P2X7 receptor: An emerging target in central nervous system diseases. *Trends in Pharmacological Sciences* **35**, 537–547 (2014).
5. Beamer, E. *et al.* Purinergic mechanisms in neuroinflammation: An update from molecules to behavior. *Neuropharmacology* **104**, 94–104 (2016).
6. Basso, A. M. *et al.* Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: Relevance for neuropsychiatric disorders. *Behav. Brain Res.* **198**, 83–90 (2009).
7. Csölle, C. *et al.* The absence of P2X7 receptors (P2rx7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice. *Int. J. Neuropsychopharmacol.* **16**, 213–233 (2013).
8. Csolle, C. *et al.* Neurochemical Changes in the Mouse Hippocampus Underlying the Antidepressant Effect of Genetic Deletion of P2X7 Receptors. *PLoS One* **8**, e66547 (2013).
9. Iwata, M. *et al.* Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor. *Biological Psychiatry* **80**, 12–22 (2016).
10. Bhattacharya, A. *et al.* Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. *Br. J. Pharmacol.* **170**, 624–640 (2013).
11. Lord, B. *et al.* Pharmacology of a Novel Central Nervous System–Penetrant P2X7 Antagonist JNJ-42253432. *J. Pharmacol. Exp. Ther.* **351**, 628–641 (2014).
12. Gubert, C. *et al.* Role of P2X7 Receptor in an Animal Model of Mania Induced by D-Amphetamine. *Mol. Neurobiol.* **53**, 611–620 (2016).
13. Krügel, U. Purinergic receptors in psychiatric disorders. *Neuropharmacology* **104**, 212–225 (2016).
14. Labrousse, V. F. *et al.* Impaired Interleukin-1 beta and c-Fos Expression in the Hippocampus Is Associated with a Spatial Memory Deficit in P2X(7) Receptor-Deficient Mice. *PLoS One* **4**, e6006 (2009).
15. Campos, R. C. *et al.* Pharmacological blockage and P2X7 deletion hinder aversive memories: Reversion in an enriched environment. *Neuroscience* **280**, 220–230 (2014).
16. Hempel, C. *et al.* The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor. *Neuropharmacology* **75**, 365–379 (2013).
17. Sperlagh, B. *et al.* Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus. *J. Neurochem.* **81**, 1196–1211 (2002).
18. Papp, L., Vizi, E. S. & Sperlagh, B. Lack of ATP-evoked GABA and glutamate release in the hippocampus of P2X7 receptor–/– mice. *Neuroreport* **15**, 2387–2391 (2004).
19. Alloisio, S. *et al.* Functional evidence for presynaptic P2X7 receptors in adult rat cerebrocortical nerve terminals. *FEBS Lett.* **582**, 3948–3953 (2008).
20. Marcoli, M. *et al.* P2X7 pre-synaptic receptors in adult rat cerebrocortical nerve terminals: A role in ATP-induced glutamate release. *J. Neurochem.* **105**, 2330–2342 (2008).
21. Insel, T. R. Rethinking schizophrenia. *Nature* **468**, 187–193 (2010).
22. Lewis, D. A. & Sweet, R. A. Schizophrenia from a neural circuitry perspective: Advancing toward rational pharmacological therapies. *Journal of Clinical Investigation* **119**, 706–716 (2009).
23. Moghaddam, B. & Javitt, D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. *Neuropsychopharmacology* **37**, 4–15 (2012).
24. Haller, J., Szirmai, M., Varga, B., Ledent, C. & Freund, T. F. Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. *Behav. Pharmacol.* **16**, 415–422 (2005).
25. Boison, D., Singer, P., Shen, H.-Y., Feldon, J. & Yee, B. K. Adenosine hypothesis of schizophrenia—opportunities for pharmacotherapy. *Neuropharmacology* **62**, 1527–1543 (2012).
26. Koch, H., Beshpalov, A., Drescher, K., Franke, H. & Krugel, U. Impaired Cognition after Stimulation of P2Y1 Receptors in the Rat Medial Prefrontal Cortex. *Neuropsychopharmacology* **40**, 305–314 (2015).
27. Geddes, A. E., Huang, X. F. & Newell, K. A. Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **35**, 896–904 (2011).
28. Mouri, A., Noda, Y., Enomoto, T. & Nabeshima, T. Phencyclidine animal models of schizophrenia: Approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. *Neurochemistry International* **51**, 173–184 (2007).
29. Neill, J. C., Harte, M. K., Haddad, P. M., Lydall, E. S. & Dwyer, D. M. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: A translational link to humans. *Eur. Neuropsychopharmacol.* **24**, 822–835 (2014).
30. Nicke, A. *et al.* A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. *J. Biol. Chem.* **284**, 25813–25822 (2009).
31. Masin, M. *et al.* Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: Re-evaluation of P2X7 knockouts. *Br. J. Pharmacol.* **165**, 978–993 (2012).
32. Wirkner, K. *et al.* Supersensitivity of P2X7 receptors in cerebrocortical cell cultures after *in vitro* ischemia. *J. Neurochem.* **95**, 1421–1437 (2005).
33. Di Cesare Mannelli, L. *et al.* Oxaliplatin evokes P2X7-dependent glutamate release in the cerebral cortex: A pain mechanism mediated by Pannexin 1. *Neuropharmacology* **97**, 133–141 (2015).
34. Ficker, C. *et al.* Astrocyte-neuron interaction in the substantia gelatinosa of the spinal cord dorsal horn via P2X7 receptor-mediated release of glutamate and reactive oxygen species. *Glia* **62**, 1671–1686 (2014).
35. Oliveira, J. F. *et al.* Rodent cortical astroglia express *in situ* functional P2X 7 receptors sensing pathologically high ATP concentrations. *Cereb. Cortex* **21**, 806–820 (2011).
36. Pankratov, Y., Lalo, U., Verkhratsky, A. & North, R. A. Vesicular release of ATP at central synapses. *Pflugers Archiv European Journal of Physiology* **452**, 589–597 (2006).
37. Cao, X. *et al.* Astrocyte-derived ATP modulates depressive-like behaviors. *Nat Med* **19**, 773–777 (2013).
38. Anastasio, N. C. & Johnson, K. M. Differential regulation of the NMDA receptor by acute and sub-chronic phencyclidine administration in the developing rat. *J. Neurochem.* **104**, 1210–1218 (2008).
39. Grimwood, S., Slater, P., Deakin, J. F. & Hutson, P. H. NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. *Neuroreport* **10**, 461–465 (1999).
40. Gao, X.-M. *et al.* Ionotropic Glutamate Receptors and Expression of N -Methyl- d -Aspartate Receptor Subunits in Subregions of Human Hippocampus: Effects of Schizophrenia. *Am. J. Psychiatry* **157**, 1141–1149 (2000).
41. Kristiansen, L. V., Patel, S. A., Haroutunian, V. & Meador-Woodruff, J. H. Expression of the NR2B-NMDA receptor subunit and its Tbr-1/CINAP regulatory proteins in postmortem brain suggest altered receptor processing in schizophrenia. *Synapse* **64**, 495–502 (2010).
42. Chaperon, F. *et al.* Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit. *Behav Pharmacol* **14**, 477–487 (2003).

43. Higgins, G. A., Ballard, T. M., Huwyler, J., Kemp, J. A. & Gill, R. Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: Evidence for an involvement of NR2B NMDA receptors in response inhibition. *Neuropharmacology* **44**, 324–341 (2003).
44. Kosowski, A. R. & Liljequist, S. The NR2B-selective N-methyl-D-aspartate receptor antagonist Ro 25-6981 [(+/-)-(R*, S*)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine propanol] potentiates the effect of nicotine on locomotor activity and dopamine release in the nucleus. *J Pharmacol Exp Ther* **311**, 560–567 (2004).
45. Mathur, P., Graybeal, C., Feyder, M., Davis, M. I. & Holmes, A. Fear memory impairing effects of systemic treatment with the NMDA NR2B subunit antagonist, Ro 25-6981, in mice: Attenuation with ageing. *Pharmacol. Biochem. Behav.* **91**, 453–460 (2009).
46. von Engelhardt, J. *et al.* Contribution of Hippocampal and Extra-Hippocampal NR2B-Containing NMDA Receptors to Performance on Spatial Learning Tasks. *Neuron* **60**, 846–860 (2008).
47. Kinney, J. W. *et al.* A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. *J. Neurosci.* **26**, 1604–1615 (2006).
48. Mei, L. & Xiong, W.-C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. *Nat. Rev. Neurosci.* **9**, 437–452 (2008).
49. Banerjee, A., MacDonald, M. L., Borgmann-Winter, K. E. & Hahn, C. G. Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome. *Brain Res. Bull.* **83**, 132–139 (2010).
50. Hashimoto, R. *et al.* Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. *Mol. Psychiatry* **9**, 299–307 (2004).
51. Law, A. J. *et al.* Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. *Proc. Natl. Acad. Sci. USA* **103**, 6747–6752 (2006).
52. Chong, V. Z. *et al.* Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. *Schizophr. Res.* **100**, 270–280 (2008).
53. O'Tuathaigh, C. M. P. *et al.* Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. *Neuroscience* **147**, 18–27 (2007).
54. Bjarnadottir, M. *et al.* Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice. *J. Neurosci.* **27**, 4519–4529 (2007).
55. Feng, Y. *et al.* Expressions of neuregulin 1β and ErbB4 in prefrontal cortex and hippocampus of a rat schizophrenia model induced by chronic MK-801 administration. *J. Biomed. Biotechnol.* **2010**, 859516 (2010).
56. du Bois, T. M., Newell, K. A. & Huang, X. F. Perinatal phencyclidine treatment alters neuregulin 1/erbB4 expression and activation in later life. *Eur. Neuropsychopharmacol.* **22**, 356–363 (2012).
57. Radonjić, N. V., Jakovčević, I., Bumbaširević, V. & Petronijević, N. D. Perinatal phencyclidine administration decreases the density of cortical interneurons and increases the expression of neuregulin-1. *Psychopharmacology (Berl)*. **227**, 673–683 (2013).
58. Braff, D. L., Geyer, M. A. & Swerdlow, N. R. Human studies of prepulse inhibition of startle: Normal subjects, patient groups, and pharmacological studies. *Psychopharmacology (Berl)* **156**, 234–258 (2001).
59. Mackeprang, T., Kristiansen, K. T. & Glenthøj, B. Y. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients. *Biol. Psychiatry* **52**, 863–873 (2002).
60. Lewis, D. A. Inhibitory neurons in human cortical circuits: Substrate for cognitive dysfunction in schizophrenia. *Current Opinion in Neurobiology* **26**, 22–26 (2014).
61. Abe, S. *et al.* Differential expression of GABA(A) receptor subunit mRNAs and ligand binding sites in rat brain following phencyclidine administration. *Synapse* **38**, 51–60 (2000).
62. Keystone, E. C. *et al.* Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. *Ann. Rheum. Dis.* **71**, 1630–1635 (2012).
63. Eser, A. *et al.* Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study. *Inflamm. Bowel Dis.* **21**, 2247–2253 (2015).
64. Wilkinson, S. M. *et al.* The first CNS-active carborane: A novel p2x7 receptor antagonist with antidepressant activity. *ACS Chem. Neurosci.* **5**, 335–339 (2014).
65. Chrovian, C. C. *et al.* Novel Phenyl-Substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 Antagonists with Robust Target Engagement in Rat Brain. *ACS Chem. Neurosci.* **7**, 490–497 (2016).
66. Solle, M. *et al.* Altered cytokine production in mice lacking P2X7 receptors. *J. Biol. Chem.* **276**, 125–132 (2001).
67. Sams-Dodd, F. Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment. *J. Neurosci. Methods* **59**, 157–167 (1995).
68. Sams-Dodd, F. Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. in *Neuroscience and Biobehavioral Reviews* **23**, 287–293 (1998).
69. Rosen, G. D., Williams, A. G., Capra, J. A., Connolly, M. T., Cruz, B., Lu, L., Airey, D. C., Kulkarni, K. & Williams, R. W. The Mouse Brain Library @ www.mbl.org. Int Mouse Genome Conference 14: 166. www.mbl.org (2000).

Acknowledgements

This study was supported by research grants from the Hungarian Research and Development Fund (Grant NN107234 and 116654 to B.S.; Grant 101645 to J.H.), the European Research Council (Grant 294313-SERRACO to B.S.), and the Hungarian Brain Research Program [KTIA_13_NAP-A-III/1 to B.S.].

Author Contributions

Conceived and design the study: L.K., J.H. and B.S. JNJ compound was donated by Janssen Research & Development (San Diego, USA), A.B. is the contact from the company. Conducted the experiments and analysed the results: B.K., C.C., S.C., A.H. and E.K. Drafted the manuscript: B.K., L.K., J.H. and B.S. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Koványi, B. *et al.* The role of P2X7 receptors in a rodent PCP-induced schizophrenia model. *Sci. Rep.* **6**, 36680; doi: 10.1038/srep36680 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016